How does Losartan (losartan) decrease the recurrence of atrial fibrillation (AFib)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 15, 2025 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

From the Guidelines

Losartan is recommended to decrease the recurrence of atrial fibrillation (AFib) due to its effects on the renin-angiotensin-aldosterone system (RAAS), which reduces blood pressure and cardiac remodeling, as evidenced by the 2024 ESC guidelines 1. The mechanism by which losartan decreases AFib recurrence is multifaceted, involving the prevention of angiotensin II binding to its receptors, thereby reducing blood pressure and decreasing cardiac remodeling, which is a major contributor to AFib development and recurrence.

  • Losartan's anti-remodeling effects develop gradually over months of consistent therapy, highlighting the importance of long-term adherence to treatment.
  • The reduction in blood pressure achieved with losartan is also crucial, as hypertension is a significant risk factor for AFib, and a 10 mmHg reduction in systolic BP has been associated with a 17% reduction in incident AF, as seen in the LIFE trial 1.
  • Additionally, losartan reduces inflammation and oxidative stress in cardiac tissue, known triggers for AFib, further supporting its use in preventing AFib recurrence.
  • In terms of dosage, losartan typically starts at 50 mg once daily, which may be increased to 100 mg daily if needed for blood pressure control, and patients should be monitored for common side effects such as dizziness and changes in blood potassium levels. The most recent and highest quality evidence supports the use of losartan, an angiotensin II receptor blocker (ARB), as a preferred agent for reducing AFib recurrence, particularly in patients with hypertension, as stated in the 2024 ESC guidelines 1.

From the Research

Mechanism of Losartan in Decreasing AFib Recurrence

  • Losartan, an angiotensin II receptor blocker, has been shown to decrease the recurrence of atrial fibrillation (AFib) in hypertensive patients 2, 3, 4, 5, 6.
  • The exact mechanism is not fully understood, but it is thought to be related to the drug's ability to inhibit atrial remodeling, which is a key factor in the development and maintenance of AFib 3, 4.
  • Atrial remodeling refers to the changes in the atrial tissue that occur in response to conditions such as hypertension, which can lead to the development of AFib 4.
  • Losartan has been shown to reduce atrial fibrosis, which is a key component of atrial remodeling, and to improve atrial conduction disturbances 3, 4.

Clinical Evidence

  • A study published in the Journal of Cardiovascular Pharmacology found that losartan was more effective than amlodipine in preventing the recurrence of AFib in hypertensive patients 2.
  • Another study published in the International Journal of Cardiology found that losartan improved atrial conduction disturbances and reduced the recurrence of AFib in patients with essential hypertension 3.
  • A study published in Cardiovascular Pathology found that losartan reduced atrial fibrosis and AFib vulnerability in a rabbit model of AFib 4.
  • The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study found that losartan reduced the incidence of new-onset AFib and subsequent stroke compared to atenolol in hypertensive patients 5.
  • A study published in Heart and Vessels found that losartan suppressed the maximum duration and total duration of paroxysmal AFib in patients with sick sinus syndrome 6.

Key Findings

  • Losartan reduces the recurrence of AFib in hypertensive patients 2, 3, 4, 5, 6.
  • Losartan inhibits atrial remodeling and reduces atrial fibrosis 3, 4.
  • Losartan improves atrial conduction disturbances and reduces AFib vulnerability 3, 4.
  • Losartan reduces the incidence of new-onset AFib and subsequent stroke in hypertensive patients 5.
  • Losartan suppresses the maximum duration and total duration of paroxysmal AFib in patients with sick sinus syndrome 6.

Related Questions

What medication should be added to amlodipine and candesartan for a patient with uncontrolled hypertension and atrial fibrillation?
What medication needs a dose adjustment in a 74-year-old male with Hypertension (HTN), paroxysmal atrial fibrillation (a fib), stage 2 Chronic Kidney Disease (CKD) and impaired renal function, taking losartan (Angiotensin II receptor antagonist), apixaban (Factor Xa inhibitor), metoprolol (Beta blocker) and morphine, also hydrocodone/acetaminophen as needed?
Is amlodipine appropriate for treating hypertension in a patient with atrial fibrillation who is also taking sotalol?
What are the next steps for a patient with atrial fibrillation (AF) and hypertension, currently on metoprolol (beta blocker), with a heart rate between 60-90 beats per minute (bpm) and systolic blood pressure of 170 mmHg?
In a 50-year-old man with recurrent atrial fibrillation/flutter despite diltiazem (240 mg) and metoprolol succinate (100 mg), and stable blood pressure on losartan (100 mg) and hydrochlorothiazide (25 mg), should amiodarone be used instead of diltiazem?
What is the management of a full-thickness rupture of the medial band of the plantar fascia?
What is the appropriate intramuscular (IM) testosterone dosing for women with hypogonadism (low testosterone)?
Does Contrave (bupropion and naltrexone) affect sperm count?
What are the alternatives to drospirenone for Oral Contraceptive Pills (OCP)?
What antibiotic is safe for pneumonia in a pregnant patient?
What are the differences between the Puestow procedure, Frey procedure, and Beger procedure?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.